Page 47 - 2019_11 Resto del Mondo-web

Novel agents in CLL
References
1. EichhorstB,FinkAM,BahloJ,etal.First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open- label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-942.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
3. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
4. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
5. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
6. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524-1537.
7. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
8. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlo- rambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
9. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunothera- py for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-43.
10. WoyachJA,RuppertAS,HeeremaNA,etal. Ibrutinib regimens versus chemoim- munotherapy in older patients with untreat- ed CLL. N Engl J Med. 2018;379(26):2517- 2528.
11. FischerK,BahloJ,FinkAM,etal.Long-term remissions after FCR chemoimmunothera- py in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
12. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and ritux- imab treatment achieves long-term disease- free survival in IGHV-mutated chronic lym- phocytic leukemia. Blood. 2016;127(3):303- 309.
13. ByrdJC,BrownJR,O'BrienS,etal.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
14. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
15. BarrPM,RobakT,OwenC,etal.Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extend- ed phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502-1510.
16. AhnIE,FarooquiMZH,TianX,etal.Depth and durability of response to ibrutinib in
CLL: 5-year follow-up of a phase 2 study.
Blood. 2018;131(21):2357-2366.
17. Ahn IE, Tian X, Albitar M, et al. Validation
of clinical prognostic models and integration of genetic biomarkers of drug resistance in CLL patients treated with ibrutinib. Blood. 2018;132(Suppl 1):186.
18. Quinquenel A, Fornecker LM, Letestu R, et al. High Prevalence of BTK Mutations on ibrutinib therapy after 3 years of treatment in a real-life cohort of CLL patients: a study from the French Innovative Leukemia Organization (FILO) Group. Blood. 2018; 132(Suppl 1):584.
19. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib- treated patients in the United States: a real- world analysis. Haematologica. 2018;103(5): 874-879.
20. Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796-1805.
21. Byrd JC, Harrington B, O'Brien S, t al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.
22. Tam C. Pooled analysis of safety data from zanubrutinib (BGB-3111) monotherapy studies in hematologic malignancies. EHA Annual Meeting. 2018;214907.
23. Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refracto- ry B-cell NHL and CLL. Oncotarget. 2018;9(16):13023-13035.
24. Reiff SD, Mantel R, Smith LL, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov. 2018;8(10):1300-1315.
25. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinosi- tol 3-kinase p110delta, for relapsed/refracto- ry chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
26. O'Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25): 2686-2694.
27. Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes fre- quent immune-mediated hepatotoxicity. Blood. 2016;128(2):195-203.
28. European Medicines Agency. EMA reviews cancer medicine Zydelig. https://wwwe- maeuropaeu/ en/news/ema-reviews-can- cer-medicine-zydelig 2016. (accessed: 11/02/2019). 2016.
29. Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumum- ab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446-2455.
30. Burris HA 3rd, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19(4):486-496.
31. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refrac- tory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120.
32. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lym- phocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36 (19):1973-1980.
33. Wierda WG, Roberts AW, Ghia P, et al. Minimal residual disease status with veneto- clax monotherapy is associated with pro- gression-free survival in chronic lymphocyt- ic Leukemia. Blood. 2018;132 (Suppl 1): 3134.
34. Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progres- sion-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131(9):955- 962.
35. Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual dis- ease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269-277.
36. Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of veneto- clax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18): 4371-4379.
37. Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353.
38. Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lympho- cytic leukemia. Nat Commun. 2018;9 (1):727.
39. Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28 (5):1050-1056.
40. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65- 75.
41. Mato AR, Tam CS, Allan JN, et al. Disease and patient characteristics, patterns of care, toxicities, and outcomes of chronic lympho- cytic leukemia (CLL) patients treated with venetoclax: a multicenter study of 204 patients. Blood. 2017;130(Suppl 1):4315.
42. Greil R, Fraser G, Leber B, et al. Efficacy and safety of ibrutinib (IBR) after venetoclax (VEN) treatment in IBR-naïve patients with relapsed/refractory (R/R) chronic lympho- cytic leukemia (CLL): follow-up of patients from the MURANO study. Blood. 2018; 132(Suppl 1):5548.
43. Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016;128(22): 638.
44. Mato AR, Schuster SJ, Lamanna N, et al. A phase 2 study to assess the safety and effica- cy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kd inhibitor therapy. J Clin Oncol. 2018;36(15_suppl):7530.
45. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612-2615.
46. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resist- ance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469-1479.
47. Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibruti-
haematologica | 2019; 104(11)
2153